Repatriation Medical Authority - Notice of Investigation - Olecranon Bursitis

Overview

The Veterans' Entitlements Act 1986 (VEA) was enacted to provide for the payment of pensions and other benefits to veterans and their dependants. The Act was introduced to address the need for a comprehensive legislative framework to support the entitlements of Australian war veterans and their families. The VEA is administered by the Repatriation Medical Authority (the Authority), which is tasked with making determinations regarding the eligibility of veterans for various benefits. The policy objective of the VEA is to ensure that veterans who have served their country receive the recognition and support they deserve. The Authority recently announced an investigation into whether Statements of Principles should be determined in respect of olecranon bursitis, inviting relevant parties to submit written evidence by a specified deadline. The investigation under section 196G of the VEA seeks to ascertain whether olecranon bursitis may be considered war-caused, defence-caused, a service injury, a service disease or a service death. The Authority is inviting submissions from a range of stakeholders, including eligible claimants, relevant organisations, and experts, to provide information and perspectives on the matter. Submissions can be made electronically through the RMA website or by other means as outlined in the notice. The Authority's decision will be informed by the evidence presented, with the aim of ensuring that veterans' entitlements are accurately assessed and appropriately supported.

Scope and Application

The Veterans' Entitlements Act 1986 (VEA) applies to a range of individuals and entities involved in matters concerning veterans and their entitlements. Specifically, this notice pertains to individuals who are eligible to make a claim for pension under Part II or Part IV of the VEA, as well as those eligible for compensation under section 319 of the Military Rehabilitation and Compensation Act 2004. Additionally, organisations representing veterans, Australian mariners, members of the Forces, members of the Peacekeeping Forces, members within the meaning of the MRCA, or their dependants are also included. The investigation is overseen by the Repatriation Medical Authority (RMA), which is mandated to determine whether there is sufficient information to warrant the establishment of Statements of Principles for olecranon bursitis. The Authority can also extend its investigation through subordinate instruments if necessary. The notice invites submissions from relevant parties and outlines the process for submitting written evidence, including electronic, email, and postal options, with a submission deadline of 23 March 2018.

Key Provisions

Section 196G of the Veterans' Entitlements Act 1986 (VEA) outlines the Repatriation Medical Authority's (the Authority) intention to conduct an investigation into whether Statements of Principles may be determined in respect of olecranon bursitis, a condition that may be suffered or contracted by veterans. This investigation is required to ascertain if this condition or death from this condition is war-caused, defence-caused, a service injury, a service disease, or a service death. To facilitate this investigation, the Authority invites eligible parties to submit written statements, including those eligible to claim pensions or compensation under the VEA or the Military Rehabilitation and Compensation Act 2004 (MRCA), organisations representing veterans or their dependents, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and experts in relevant fields. The Authority has outlined a submission process that allows interested parties to electronically lodge their submissions and supporting information via the RMA website. Alternatively, submissions can be sent by email or posted to a specified address. The RMA Submission Guidelines are available online to assist with the preparation of submissions. The deadline for receiving these submissions is 23 March 2018, well before the first meeting scheduled for 4 April 2018. This structured submission process ensures that the Authority receives relevant and comprehensive information from stakeholders, enabling it to make informed decisions about the potential inclusion of olecranon bursitis in Statements of Principles. Entities and individuals subject to the provisions of the VEA and those who wish to participate in the investigation are obligated to adhere to the specified submission guidelines and deadlines. The requirement to submit written submissions within the stipulated timeframe is crucial to ensure that all relevant information is considered in the investigation. Furthermore, the Authority's invitation to submit written statements from a broad range of stakeholders, including veterans, their representatives, and experts, underscores the importance of a comprehensive and inclusive approach to the investigation. This inclusive approach aims to capture diverse perspectives and expert insights, which are essential for a thorough and balanced assessment of the condition in question. Failure to comply with the submission requirements may have legal consequences, although the VEA does not explicitly detail penalties for non-compliance. However, the importance of the investigation and the need for comprehensive stakeholder input suggest that any breach of these submission requirements could be viewed seriously by the Authority. The Authority may consider non-compliance as a failure to contribute to the investigation's objectives, potentially impacting the outcome of the investigation. While the VEA does not explicitly state penalties for non-compliance, the implications of not adhering to the submission process could include the exclusion of relevant information from the investigation, potentially affecting the determination of Statements of Principles related to olecranon bursitis.